Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome-Reference-Cited by-同舟云学术

Mesalazine (5-aminosalicylic acid) alters faecal bacterial profiles, but not mucosal proteolytic activity in diarrhoea-predominant irritable bowel syndrome

Published:2011-06-14 Issue:3 Volume:34 Page:374-383
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:

Author:

Andrews C. N.,Griffiths T. A.,Kaufman J.,Vergnolle N.,Surette M. G.,Rioux K. P.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.2011.04732.x/fullpdf

Reference44 articles.

1. AGA technical review on irritable bowel syndrome;Drossman;Gastroenterology,2002

2. Review article: the psychoneuroimmunology of irritable bowel syndrome - an exploration of interactions between psychological, neurological and immunological observations;Arebi;Aliment Pharmacol Ther,2008

3. Dysbiosis in inflammatory bowel disease;Tamboli;Gut,2004

4. The fecal microbial population in the irritable bowel syndrome;Balsari;Microbiologica,1982

5. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects;Kassinen;Gastroenterology,2007

Cited by 81 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The colon targeting efficacies of mesalazine medications and their impacts on the gut microbiome;Journal of Controlled Release;2024-05

2. Gut microb-aging and its relevance to frailty aging;Microbes and Infection;2024-03

3. Changes in intestinal microbiota and biochemical parameters in patients with inflammatory bowel disease and irritable bowel syndrome induced by the prolonged addition of soluble fibers to usual drug therapy;The Journal of Medical Investigation;2024

4. Interplay between inflammatory bowel disease therapeutics and the gut microbiome reveals opportunities for novel treatment approaches;Microbiome Research Reports;2023-09-26

5. Microbiota-sensitive drug delivery systems based on natural polysaccharides for colon targeting;Drug Discovery Today;2023-07